GLP-1 drugs have shown promise in cutting the risk of cancer, according to an academic study. However, this potential benefit was overshadowed by disappointing hepatitis B test results and a stock offering from pharmaceutical company Gyre. Researchers observed that GLP-1 medications may have anti-cancer properties, suggesting new avenues for treatment. In contrast, Gyre’s recent data failed to impress investors, causing its stock price to plummet. The news also comes as other pharmaceutical companies, including Sanofi, Servier, and Zentiva, announce their latest developments in the field of GLP-1 drugs and related treatments.
Source: https://endpts.com/glp-1s-may-cut-cancer-risk-gyres-stock-falls-after-hepatitis-c-data-and-offering